These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 18203522)

  • 1. Effect of Chinese herbal medicine on overactive bladder.
    Ogushi T; Takahashi S
    Hinyokika Kiyo; 2007 Dec; 53(12):857-62. PubMed ID: 18203522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical efficacy and tolerability of gosha-jinki-gan, Japanese traditional herbal medicine, in females with overactive bladder.
    Kajiwara M; Mutaguchi K
    Hinyokika Kiyo; 2008 Feb; 54(2):95-9. PubMed ID: 18323165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
    Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
    Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
    Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
    BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effectiveness and safety of naftopidil for benign prostatic hyperplasia patients with overactive bladder symptoms].
    Ge JP; Gong J; Ma HQ; Wei W; Shang XJ; Zhang ZY; Xu S; Wang D; Gao JP
    Zhonghua Nan Ke Xue; 2008 Oct; 14(10):927-30. PubMed ID: 19157107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Fushile: a safe and effective therapeutic for benign prostatic hyperplasia].
    Shang XJ; Liu ZY; Liu ZF; Sun YH; Huang YF
    Zhonghua Nan Ke Xue; 2008 Mar; 14(3):227-30. PubMed ID: 18488335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gosha-jinki-gan reduces transmitter proteins and sensory receptors associated with C fiber activation induced by acetic acid in rat urinary bladder.
    Imamura T; Ishizuka O; Aizawa N; Zhong C; Ogawa T; Nakayama T; Tanabe T; Nishizawa O
    Neurourol Urodyn; 2008; 27(8):832-7. PubMed ID: 18551569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.
    Chapple C; Herschorn S; Abrams P; Sun F; Brodsky M; Guan Z
    Eur Urol; 2009 Sep; 56(3):534-41. PubMed ID: 19070418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
    Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
    BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Symptom assessment tool for overactive bladder syndrome--overactive bladder symptom score.
    Homma Y; Yoshida M; Seki N; Yokoyama O; Kakizaki H; Gotoh M; Yamanishi T; Yamaguchi O; Takeda M; Nishizawa O
    Urology; 2006 Aug; 68(2):318-23. PubMed ID: 16904444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
    Roehrborn CG; Kaplan SA; Kraus SR; Wang JT; Bavendam T; Guan Z
    Urology; 2008 Nov; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size.
    Roehrborn CG; Kaplan SA; Jones JS; Wang JT; Bavendam T; Guan Z
    Eur Urol; 2009 Feb; 55(2):472-9. PubMed ID: 18583022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between improvements in Overactive Bladder Symptom Score and health-related quality of life questionnaires in overactive bladder patients treated with an antimuscarinic drug.
    Kubota Y; Kojima Y; Shibata Y; Imura M; Kohri K; Sasaki S
    Neurourol Urodyn; 2011 Sep; 30(7):1309-14. PubMed ID: 21560155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
    Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
    Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety, tolerability, and efficacy of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder.
    Homma Y; Yamaguchi O
    Int J Urol; 2008 Oct; 15(11):986-91. PubMed ID: 18761536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
    Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
    Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Solifenacin treatment for overactive bladder in Hispanic patients: patient-reported symptom bother and quality of life outcomes from the VESIcare Open-Label Trial.
    Capo' JP; Laramée C; Lucente V; Fakhoury A; Forero-Schwanhaeuser S
    Int J Clin Pract; 2008 Jan; 62(1):39-46. PubMed ID: 18036164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency.
    Kaplan SA; McCammon K; Fincher R; Fakhoury A; He W
    J Urol; 2009 Dec; 182(6):2825-30. PubMed ID: 19837435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A role of intravesical capsaicin instillation in benign prostatic hyperplasia with overactive bladder symptoms: the first reported study in the literature.
    Mahawong P; Chaiyaprasithi B; Soontrapa S; Tappayuthapijarn P
    J Med Assoc Thai; 2007 Nov; 90(11):2301-9. PubMed ID: 18181311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding the elements of overactive bladder: questions raised by the EPIC study.
    Irwin DE; Abrams P; Milsom I; Kopp Z; Reilly K;
    BJU Int; 2008 Jun; 101(11):1381-7. PubMed ID: 18336602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.